29. Overview of all interventions in the serious adverse events analysis.

Treatment	RCTs	Participants
Antidepressants with ≥ 200 participants
Desvenlafaxine high dose	2	691
Duloxetine high dose	12	1803
Duloxetine low dose	4	473
Duloxetine standard dose	15	2507
Esreboxetine high dose	1	281
Esreboxetine standard dose	1	556
Milnacipran high dose	7	1569
Milnacipran standard dose	7	1240
Milnacipran dose unable to be categorised	3	203
Mirtazapine standard dose	3	243
Antidepressants with < 200 participants (excluded from summaries)
Amitriptyline high dose	1	96
Amitriptyline low dose	1	32
Amitriptyline standard dose	3	114
Amitriptyline dose unable to be categorised	1	25
Bupropion standard dose	1	54
Citalopram standard dose	2	34
Desipramine low dose	1	38
Desipramine + cognitive behavioural therapy	1	37
Desvenlafaxine standard dose	2	199
Esreboxetine dose unable to be categorised	1	134
Imipramine low dose	1	18
Imipramine standard dose	1	51
Milnacipran standard + cognitive behavioural therapy	1	17
Mirtazapine low dose	1	26
Nortriptyline low dose	2	137
Nortriptyline unable to be categorised	1	56
Nortriptyline unable to be categorised + cognitive behavioural therapy	1	41
Nortriptyline unable to be categorised + disease management	1	37
Paroxetine low dose	2	62
Paroxetine dose unable to be categorised	2	152
Reboxetine standard dose	1	18
Sertraline high dose	1	30
Trazadone + gabapentin	1	94
Venlafaxine high dose	1	82
Venlafaxine low dose	1	82
Venlafaxine standard dose	1	86
Non‐antidepressant interventions (excluded from summaries)
Carbamazepine	2	99
Cognitive behavioural therapy	3	72
Coping skills training	1	29
Disease management	1	24
Gabapentin	2	56
Nabilone	1	32
Pregabalin	3	643
Terbutaline	1	51
RCT: randomised controlled trial Participant numbers reflect the total number of participants receiving the antidepressant.